



# GASTRO FLORIDA BIOLOGICS PROGRAM



## Peace of Mind

You are currently using or about to start using immunosuppressive drug therapy to treat your Crohn's or Colitis Inflammatory Bowel Disease (IBD).



## Early Detection

By having IBD, and due to the nature of the biologic drug therapy used to treat these conditions, you are more vulnerable or susceptible to infections, including sexually transmitted infections (STI).



## Essential Testing

As often required for insurance authorizations, we will include Tuberculosis (TB), Hepatitis, and HIV testing as part of your lab panel/rapid testing and STI screening.



## Established Support

To facilitate your medication treatment process, including financial assistance, prescription refills, and screenings, our Program Manager, Dilcia Hernandez, will reach out to you directly.

**Giving you the power to protect your peace.**

Gastro Florida  
3001 Executive Dr. Ste. 130  
Clearwater, FL 33762

Please contact  
**Dilcia Hernandez,**  
**Program Manager,** with  
any questions regarding  
this process.

 **727-888-1818**

 **dehernandez@gastrofl.com**

 **www.gastrofl.com**

## References



Rahier, J.F., et al. "Second European Evidence-Based Consensus on the Prevention, Diagnosis and Management of Opportunistic Infections in Inflammatory Bowel Disease." *Journal of Crohn's and Colitis*, vol. 8, no. 6, June 2014, pp. 443-468, <https://doi.org/10.1016/j.crohns.2013.12.013>.



Bonovas, Stefanos, et al. "Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis." *Clinical Gastroenterology and Hepatology*, vol. 14, no. 10, 2016, pp. 1385-1397.e10, <https://doi.org/10.1016/j.cgh.2016.01.023>.



Kirchgesner, Julien, et al. "Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases." *Gastroenterology*, vol. 155, no. 2, 2018, pp. 337-346.e10, <https://doi.org/10.1053/j.gastro.2018.04.012>.